The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 4, 2007, Pages 798-807

  Steffensen, K D ^a,b,c   Waldstrom M ^a   Jeppesen, U ^b   Jakobsen, E ^a   Brandslund, I ^a   Jakobsen, A ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b HORSENS REGIONAL HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

COX2; HER2 amplification; HER2 overexpression; Ovarian cancer; Prognostic marker

Indexed keywords

CARBOPLATIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; EPITHELIUM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; UNIVARIATE ANALYSIS;

ADULT; AGED; CYCLOOXYGENASE 2; EPITHELIAL CELLS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 34447327852     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00855.x     Document Type: Article

References (44)

1. Thigpen JT. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 2000 27 (Suppl. 7 11 6.
2. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999 18: 305 14.
3. Erkinheimo TL, Lassus H, Finne P et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 2004 10: 538 45.
4. Ferrandina G, Ranelletti FO, Lauriola L et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 2002 85: 305 10.
5. Ali-Fehmi R, Morris RT, Bandyopadhyay S et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 2005 192: 819 25.
6. Khalifeh I, Munkarah AR, Lonardo F et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol 2004 23: 162 9.
7. Denkert C, Kobel M, Pest S et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002 160: 893 903.
8. Ferrandina G, Lauriola L, Zannoni GF et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002 13: 1205 11.
9. Seo SS, Song YS, Kang DH et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 2004 92: 927 35.
10. Raspollini MR, Amunni G, Villanucci A, Boddi V, Taddei GL. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer. Acta Obstet Gynecol Scand 2006 85: 493 98.
11. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001 2: 127 37.
12. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001 61: 2420 3.
13. Wiechen K, Dietel M. c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Int J Cancer 1995 63: 604 8.
14. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993 53: 891 8.
15. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003 21: 283 90.
16. Hogdall EV, Christensen L, Kjaer SK et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003 98: 66 73.
17. Meden H, Marx D, Roegglen T, Schauer A, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 1998 17: 61 5.
18. Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997 71: 173 9.
19. Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol 1995 21: 167 78.
20. Meden H, Marx D, Rath W et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994 13: 45 53.
21. Felip E, del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995 75: 2147 52.
22. Tanner B, Kreutz E, Weikel W et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol 1996 62: 268 77.
23. Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990 50: 4087 91.
24. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244: 707 12.
25. Hengstler JG, Lange J, Kett A et al. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 1999 59: 3206 14.
26. Verri E, Guglielmini P, Puntoni M et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005 68: 154 61.
27. Hornung R, Urs E, Serenella E et al. Analysis of potential prognostic factors in 111 patients with ovarian cancer. Cancer Lett 2004 206: 97 106.
28. Fajac A, Benard J, Lhomme C et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 1995 64: 146 51.
29. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 1993 168 (Pt 1 162 9.
30. Singleton TP, Perrone T, Oakley G et al. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. Cancer 1994 73: 1460 6.
31. Medl M, Sevelda P, Czerwenka K et al. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol 1995 59: 321 6.
32. Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol 2000 17: 103 6.
33. Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 1999 111: 311 6.
34. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004 14: 1086 96.
35. Jakobsen A, Bertelsen K, Andersen JE et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997 15: 193 8.
36. Jakobsen A, Bertelsen K, Andersen JE et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 2002 7 (1 34 40. Classic Papers and Current Comments. (Authors' update 2002.)
37. Lassus H, Leminen A, Vayrynen A et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004 92: 31 9.
38. Mayr D, Kanitz V, Amann G et al. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 2006 48: 149 56.
39. Mano MS, Awada A, Di Leo A et al. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol 2004 92: 887 95.
40. Peethambaram PP, Cliby WA, Lubiniecki G et al. Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. Gynecol Oncol 2003 89: 99 104.
41. Kupryjanczyk J, Madry R, Plisiecka-Halasa J et al. TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer 2004 91: 1916 23.
42. Coffey RJ, Hawkey CJ, Damstrup L et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997 94: 657 62.
43. Wang SC, Lien HC, Xia W et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004 6: 251 61.
44. Singhal PK, Spiegel G, Driscoll D, Odunsi K, Lele S, Rodabaugh KJ. Cyclooxygenase 2 expression in serous tumors of the ovary. Int J Gynecol Pathol 2005 24: 62 6.